Dermatite Atópica: A Nova Revolução Terapêutica na Dermatologia by Torres, T.
PE
R
SP
EC
TI
VA
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                669
Atopic Dermatitis: The New Therapeutic Revolution in 
Dermatology
Dermatite Atópica: A Nova Revolução Terapêutica na 
Dermatologia
1. Serviço de Dermatologia. Centro Hospitalar e Universitário do Porto. Porto. Portugal.
2. Mestrado Integrado em Medicina. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto. Portugal.
 Autor correspondente: Tiago Torres. torres.tiago@outlook.com
Recebido: 13 de outubro de 2017 - Aceite: 25 de outubro de 2017 | Copyright © Ordem dos Médicos 2017
Tiago TORRES1,2
Acta Med Port 2017 Oct;30(10):669-670  ▪  https://doi.org/10.20344/amp.9787
Keywords: Dermatitis, Atopic/physiopathology; Dermatitis, Atopic/therapy; Molecular Targeted Therapy
Palavras-chave: Dermatite Atópica/fisiopatologia; Dermatite Atópica/tratamento; Terapia de Alvo Molecular
 Biologic agents revolutionized the management of 
psoriasis over the past decade, leading to a significant 
shift in the treatment of this chronic disorder that invariably 
requires long-term therapy to maintain clinical response.1 
This revolution was mainly due to the major advances 
made in the past 30 years in elucidating the pathogenesis 
of psoriasis: first identifying the role of TNF and later the 
key role of IL-23/IL-17 axis in psoriatic inflammation.2 A 
similar revolution is currently being observed in atopic 
dermatitis (AD), as a growing understanding of the 
molecular mechanisms that contribute to AD is enabling the 
development of new targeted therapies.
 AD is a common, chronic and relapsing inflammatory 
skin disorder with an increasing incidence during the 
past few decades, especially in developed countries.3 
It is associated with significant morbidity and quality of 
life impairment, and recent studies have demonstrated a 
burden of disease comparable to other chronic conditions 
like diabetes mellitus and cystic fibrosis.4 Active disease has 
major psychosocial and financial implications for individuals, 
their families, health care providers, and society as a whole. 
Moreover, AD has been put forward as a systemic disorder 
associated with increased risk of various medical and 
psychiatric comorbidities, just like psoriasis, although in a 
lesser degree.5
 Contrary to psoriasis, the treatment of moderate-to-
severe AD remained challenging and limited. Cyclosporine 
is the only systemic agent approved for the treatment of AD 
in many European countries and alternative off-label options 
include methotrexate, azathioprine and mycophenolate-
mofetil, with similar response rates, but limited by their 
safety profile. Thus, the need for novel, efficacious, safe 
and targeted treatments is at its greatest. 
 The pathogenesis of AD is complex and combines 
barrier dysfunction, cutaneous and systemic immune 
dysregulation and the role of microbiome.6 During the 
past decade, the underlying molecular basis for AD has 
been increasingly understood as well as for pruritus, both 
at the peripheral and central nervous system levels. AD is 
characterized by skin epidermal barrier disruption which 
leads to chronic inflammation with epidermal hyperplasia 
and cellular infiltrates, including T-cells, dendritic cells, 
eosinophils, and type-2 T-helper cell (Th2).6 Regarding 
immune dysregulation, AD is currently considered a 
biphasic or combined T cell-mediated disease. A Th2 signal 
predominates in the acute phase, secreting IL-4, IL-5, IL-
13, IL-25, and IL-31, whereas a Th2–Th1 switch promotes 
disease chronicity. Moreover, a Th22 cells secreting IL-22, 
and in a smaller degree, Th17 cells secreting IL-17 play 
a role in the initiation and maintenance of AD.6 Finally, 
although IgE has been considered a hallmark of atopic 
diseases, including AD, IgE itself is not a key mediator of 
AD pathogenesis.6
 This growing understanding of the mechanism for AD, 
particularly focused on suppressing the skewed immune 
activation, is leading to an expanding pipeline of new 
and targeted topical and systemic therapies. In the past 
year, the first topical PDE4 inhibitor (crisaborole) and 
the first effective subcutaneously administered biologic 
(dupilumab) targeting the IL-4/IL-13 receptor, that received 
the ‘breakthrough therapy’ designation of and priority 
review by the US Food and Drug Administration (FDA), 
have become available for mild-to-moderate and moderate-
to-severe AD, respectively.7,8 Several other topical, oral 
and injectable therapies are currently being studied in AD. 
Pitrakinra specifically blocks IL-4, while tralokinumab and 
lebrikizumab selectively targets IL-13. Nemolizumab, an IL-
31 receptor inhibitor, is the first biologic specifically targeting 
IL-31, also known as the ‘pruritus cytokine’, and has shown 
to significantly inhibit pruritus in the phase two clinical trial. 
As expected, the anti-IgE biologic omalizumab did not show 
efficacy in clinical trials.8,9
 Janus kinases (JAK) inhibitors are another promising 
therapeutic class for the treatment of AD. JAK-STAT (Janus 
kinase - signal transducer and activator of transcription) 
is an intracellular signaling pathway on which many 
different proinflammatory cytokines (including IL-4, IL-5, 
IL-13, and IL-31) elicit their pathophysiologic functions. 
JAK inhibitors are broad-acting small molecules for oral 
or topical administration, with anti-inflammatory and 
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anti-proliferative activity. Oral baricitinib (JAK1/2 inhibitor; 
phase two completed), PF-04965842 (JAK1 inhibitor; in 
phase two) and upadacitinib (JAK1 inhibitor; in phase two) 
are currently being evaluated in AD, while INCB18424 
(JAK1/2 inhibitor) and LEO 124249/JTE-052 (Pan-JAK 
inhibitor; in trials in Japan), are in phase two clinical trials 
for topical administration.8,9 Large, randomized, placebo-
controlled clinical trials are eagerly waited to clarify the 
potential benefit of JAK inhibitors in AD patients.
 Many of these therapies are also being investigated 
in other diseases, such as asthma, chronic obstructive 
pulmonary disease or allergic disorders. Thus, just like it 
happened in psoriasis, another successful therapeutic 
transfer from dermatology to other medical areas may be 
repeated.
 We are living exciting times in AD. Several mechanistic 
studies are now allowing the identification of key mediators 
and mechanisms that drive and perpetuate AD, leading to 
the development of several new and targeted therapies, 
revitalizing this previously stagnant field, that will change 
dermatological praxis profoundly and will increase 
physicians’ ability to help to improve the patients’ lives. 
However, despite overall confidence we still have to be 
aware of unexpected risks. Although the side effect profile 
of these new drugs appears safe, long-term effects are still 
unclear.
 Researchers and dermatologists must now focus on 
better defining different subtypes of AD, being able to early 
identify those patients which are in the need of a maximum 
treatment. These new directed therapies will change current 
algorithms of care and its careful use will allow practitioners 
to provide optimal therapy while minimizing adverse impacts 
on safety and cost.
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